The ESSENCE trial showed that 63% of patients on Wegovy achieved MASH resolution compared to 34% on placebo, and 37% had improvement in liver fibrosis compared to 22% on placebo
When needed, we may have you wait a short time after your first injection
Then, we can create a detailed plan that fits your unique situation
Well, if I'm an endocrinologist, there are light bulbs going off in my head right now because I'm saying, that sounds like a great treatment for type 2 diabetes
Hyperosmolar hyperglycaemic state (HHS) is a more relevant concern for people with type 2 diabetes experiencing severe hyperglycaemia
PFK-158, the first specific 6-phosphofructo-2-kinase (PFKFB3) inhibitor, has shown broad antitumor activity in a variety of human and preclinical models, and the clinical value of PFK-158 in patients with advanced pancreatic cancer has been reported in a related multicenter clinical trial (NCT02044861) [92]